In vivo evaluation of the novel calcineurin inhibitor ISATX247 in Non-Human primates

Mario Stalder, Tudor Bîrsan, Richard W. Hubble, Ricardo T. Paniagua, Randall E. Morris

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: ISATX247 is a novel calcineurin inhibitor that has shown more potency than cyclosporine in vitro. This is the first in vivo study of the effects of ISATX247 on lymphocyte functions in non-human primates. Methods: Groups of cynomolgus monkeys were treated orally twice daily for 7 days, each dose consisting of 25 mg/kg cyclosporine (n = 5), 25 mg/kg ISATX247 (n = 6) or 50 mg/kg ISATX247 (n = 6). Levels of cyclosporine and ISATX247 in whole blood were measured by liquid chromatography/mass spectrometry. After mitogen stimulation, lymphocyte proliferation was assessed by tritium-labeled thymidine incorporation and by flow cytometry (expression of proliferating cell nuclear antigen in cells in S/G2M phase). Flow cytometry was also used to assess production of intracellular cytokines by T cells (interleukin-2, interferon-γ, tumor necrosis factor-α) and expression of T-cell surface activation antigens (CD25, CD71, CD11a, CD95, CD154). Results: Trough (C14hr) and peak (C3hr) drug levels, as well as area under the concentration-time curve, were significantly higher for cyclosporine than ISATX247 (370 ng/ml vs 70 ng/ml, 877 ng/ml vs 303 ng/ml and 6,262 ng · h/ml vs 1,979 ng · h/ml, respectively). On Day 7 at C14hr, lymphocyte proliferation had been suppressed by approximately 50% in all groups compared with proliferation before treatment. Three hours after dosing, lymphocyte proliferation was inhibited significantly more by ISATX247 (approximately 80%, with no differences between the two ISATX247 dose levels) than by cyclosporine (65% inhibition). Similar differences between the immunosuppressive effects of ISATX247 and cyclosporine were found for inhibition of expression of T-cell surface activation antigens. Despite lower ISATX247 exposures compared with cyclosporine, the cyclosporine treatment only rarely suppressed cytokine production more than treatment with ISATX247. Conclusions: In non-human primates, ISA TX247 produces a greater or similar inhibition of lymphocyte proliferation, expression of T-cell activation surface antigens, and cytokine production when compared with cyclosporine, despite ISATX247's lower blood levels and total exposure. We conclude that ISATX247 suppresses diverse T-cell functions more potently than cyclosporine in non-human primates in vivo.

Original languageEnglish (US)
Pages (from-to)1343-1352
Number of pages10
JournalJournal of Heart and Lung Transplantation
Volume22
Issue number12
DOIs
StatePublished - Dec 2003

Fingerprint

Primates
Cyclosporine
CD27 Antigens
Lymphocytes
Surface Antigens
Cytokines
Calcineurin Inhibitors
voclosporin
Flow Cytometry
T-Lymphocytes
Macaca fascicularis
Tritium
Proliferating Cell Nuclear Antigen
Immunosuppressive Agents
S Phase
Mitogens
Liquid Chromatography
Thymidine
Interferons
Interleukin-2

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

In vivo evaluation of the novel calcineurin inhibitor ISATX247 in Non-Human primates. / Stalder, Mario; Bîrsan, Tudor; Hubble, Richard W.; Paniagua, Ricardo T.; Morris, Randall E.

In: Journal of Heart and Lung Transplantation, Vol. 22, No. 12, 12.2003, p. 1343-1352.

Research output: Contribution to journalArticle

Stalder, Mario ; Bîrsan, Tudor ; Hubble, Richard W. ; Paniagua, Ricardo T. ; Morris, Randall E. / In vivo evaluation of the novel calcineurin inhibitor ISATX247 in Non-Human primates. In: Journal of Heart and Lung Transplantation. 2003 ; Vol. 22, No. 12. pp. 1343-1352.
@article{55c7427bd04b4e3797f4fe1893fc02ea,
title = "In vivo evaluation of the novel calcineurin inhibitor ISATX247 in Non-Human primates",
abstract = "Background: ISATX247 is a novel calcineurin inhibitor that has shown more potency than cyclosporine in vitro. This is the first in vivo study of the effects of ISATX247 on lymphocyte functions in non-human primates. Methods: Groups of cynomolgus monkeys were treated orally twice daily for 7 days, each dose consisting of 25 mg/kg cyclosporine (n = 5), 25 mg/kg ISATX247 (n = 6) or 50 mg/kg ISATX247 (n = 6). Levels of cyclosporine and ISATX247 in whole blood were measured by liquid chromatography/mass spectrometry. After mitogen stimulation, lymphocyte proliferation was assessed by tritium-labeled thymidine incorporation and by flow cytometry (expression of proliferating cell nuclear antigen in cells in S/G2M phase). Flow cytometry was also used to assess production of intracellular cytokines by T cells (interleukin-2, interferon-γ, tumor necrosis factor-α) and expression of T-cell surface activation antigens (CD25, CD71, CD11a, CD95, CD154). Results: Trough (C14hr) and peak (C3hr) drug levels, as well as area under the concentration-time curve, were significantly higher for cyclosporine than ISATX247 (370 ng/ml vs 70 ng/ml, 877 ng/ml vs 303 ng/ml and 6,262 ng · h/ml vs 1,979 ng · h/ml, respectively). On Day 7 at C14hr, lymphocyte proliferation had been suppressed by approximately 50{\%} in all groups compared with proliferation before treatment. Three hours after dosing, lymphocyte proliferation was inhibited significantly more by ISATX247 (approximately 80{\%}, with no differences between the two ISATX247 dose levels) than by cyclosporine (65{\%} inhibition). Similar differences between the immunosuppressive effects of ISATX247 and cyclosporine were found for inhibition of expression of T-cell surface activation antigens. Despite lower ISATX247 exposures compared with cyclosporine, the cyclosporine treatment only rarely suppressed cytokine production more than treatment with ISATX247. Conclusions: In non-human primates, ISA TX247 produces a greater or similar inhibition of lymphocyte proliferation, expression of T-cell activation surface antigens, and cytokine production when compared with cyclosporine, despite ISATX247's lower blood levels and total exposure. We conclude that ISATX247 suppresses diverse T-cell functions more potently than cyclosporine in non-human primates in vivo.",
author = "Mario Stalder and Tudor B{\^i}rsan and Hubble, {Richard W.} and Paniagua, {Ricardo T.} and Morris, {Randall E.}",
year = "2003",
month = "12",
doi = "10.1016/S1053-2498(03)00033-0",
language = "English (US)",
volume = "22",
pages = "1343--1352",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - In vivo evaluation of the novel calcineurin inhibitor ISATX247 in Non-Human primates

AU - Stalder, Mario

AU - Bîrsan, Tudor

AU - Hubble, Richard W.

AU - Paniagua, Ricardo T.

AU - Morris, Randall E.

PY - 2003/12

Y1 - 2003/12

N2 - Background: ISATX247 is a novel calcineurin inhibitor that has shown more potency than cyclosporine in vitro. This is the first in vivo study of the effects of ISATX247 on lymphocyte functions in non-human primates. Methods: Groups of cynomolgus monkeys were treated orally twice daily for 7 days, each dose consisting of 25 mg/kg cyclosporine (n = 5), 25 mg/kg ISATX247 (n = 6) or 50 mg/kg ISATX247 (n = 6). Levels of cyclosporine and ISATX247 in whole blood were measured by liquid chromatography/mass spectrometry. After mitogen stimulation, lymphocyte proliferation was assessed by tritium-labeled thymidine incorporation and by flow cytometry (expression of proliferating cell nuclear antigen in cells in S/G2M phase). Flow cytometry was also used to assess production of intracellular cytokines by T cells (interleukin-2, interferon-γ, tumor necrosis factor-α) and expression of T-cell surface activation antigens (CD25, CD71, CD11a, CD95, CD154). Results: Trough (C14hr) and peak (C3hr) drug levels, as well as area under the concentration-time curve, were significantly higher for cyclosporine than ISATX247 (370 ng/ml vs 70 ng/ml, 877 ng/ml vs 303 ng/ml and 6,262 ng · h/ml vs 1,979 ng · h/ml, respectively). On Day 7 at C14hr, lymphocyte proliferation had been suppressed by approximately 50% in all groups compared with proliferation before treatment. Three hours after dosing, lymphocyte proliferation was inhibited significantly more by ISATX247 (approximately 80%, with no differences between the two ISATX247 dose levels) than by cyclosporine (65% inhibition). Similar differences between the immunosuppressive effects of ISATX247 and cyclosporine were found for inhibition of expression of T-cell surface activation antigens. Despite lower ISATX247 exposures compared with cyclosporine, the cyclosporine treatment only rarely suppressed cytokine production more than treatment with ISATX247. Conclusions: In non-human primates, ISA TX247 produces a greater or similar inhibition of lymphocyte proliferation, expression of T-cell activation surface antigens, and cytokine production when compared with cyclosporine, despite ISATX247's lower blood levels and total exposure. We conclude that ISATX247 suppresses diverse T-cell functions more potently than cyclosporine in non-human primates in vivo.

AB - Background: ISATX247 is a novel calcineurin inhibitor that has shown more potency than cyclosporine in vitro. This is the first in vivo study of the effects of ISATX247 on lymphocyte functions in non-human primates. Methods: Groups of cynomolgus monkeys were treated orally twice daily for 7 days, each dose consisting of 25 mg/kg cyclosporine (n = 5), 25 mg/kg ISATX247 (n = 6) or 50 mg/kg ISATX247 (n = 6). Levels of cyclosporine and ISATX247 in whole blood were measured by liquid chromatography/mass spectrometry. After mitogen stimulation, lymphocyte proliferation was assessed by tritium-labeled thymidine incorporation and by flow cytometry (expression of proliferating cell nuclear antigen in cells in S/G2M phase). Flow cytometry was also used to assess production of intracellular cytokines by T cells (interleukin-2, interferon-γ, tumor necrosis factor-α) and expression of T-cell surface activation antigens (CD25, CD71, CD11a, CD95, CD154). Results: Trough (C14hr) and peak (C3hr) drug levels, as well as area under the concentration-time curve, were significantly higher for cyclosporine than ISATX247 (370 ng/ml vs 70 ng/ml, 877 ng/ml vs 303 ng/ml and 6,262 ng · h/ml vs 1,979 ng · h/ml, respectively). On Day 7 at C14hr, lymphocyte proliferation had been suppressed by approximately 50% in all groups compared with proliferation before treatment. Three hours after dosing, lymphocyte proliferation was inhibited significantly more by ISATX247 (approximately 80%, with no differences between the two ISATX247 dose levels) than by cyclosporine (65% inhibition). Similar differences between the immunosuppressive effects of ISATX247 and cyclosporine were found for inhibition of expression of T-cell surface activation antigens. Despite lower ISATX247 exposures compared with cyclosporine, the cyclosporine treatment only rarely suppressed cytokine production more than treatment with ISATX247. Conclusions: In non-human primates, ISA TX247 produces a greater or similar inhibition of lymphocyte proliferation, expression of T-cell activation surface antigens, and cytokine production when compared with cyclosporine, despite ISATX247's lower blood levels and total exposure. We conclude that ISATX247 suppresses diverse T-cell functions more potently than cyclosporine in non-human primates in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0345735942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345735942&partnerID=8YFLogxK

U2 - 10.1016/S1053-2498(03)00033-0

DO - 10.1016/S1053-2498(03)00033-0

M3 - Article

C2 - 14672749

AN - SCOPUS:0345735942

VL - 22

SP - 1343

EP - 1352

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 12

ER -